Acorda to Present New Analyses of Cimaglermin alfa (GGF2) Data at the 64th Annual ACC Scientific Session
March 10 2015 - 07:00AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present new
analyses of data from a Phase 1 clinical trial of cimaglermin alfa
(GGF2), an investigative drug for heart failure, at the American
College of Cardiology 64th Annual Scientific Session and Expo
(ACC). The meeting is being held in San Diego, CA, March 14-16.
"Cimaglermin alfa represents a novel approach to the development
of treatment options for heart failure, potentially acting directly
to strengthen the heart and improve its ability to pump blood.
Current standard of care medications control blood pressure, fluid
volume and neurohormonal activation that contribute to ongoing
damage. Even with optimized care, the prognosis for people with
advanced heart failure is poor. More effective treatments are
needed for the 5.1 million Americans living with heart failure,"
said Anthony Caggiano, M.D., Ph.D., Senior Vice President of
Research and Development at Acorda. "In the Phase 1 trial,
cimaglermin alfa improved ejection fraction, a measure of heart
function, for as long as 90 days after a single dose. This
improvement was observed on top of optimized medical therapy.
Results from this trial helped inform our ongoing Phase 1b
trial."
"Sustained Improvements in Cardiac Function with Single Dose
Cimaglermin Alfa (GGF2) in Human Left Ventricular Systolic
Dysfunction" (Poster #1146-212) will be exhibited in Poster Hall B1
on Saturday, March 14th, 1:30-4:30. Daniel Lenihan, M.D., Professor
of Medicine and Director, Clinical Research at the Vanderbilt
University Medical Center, Division of Cardiovascular Medicine is
the lead author and will present the poster.
More detailed information on the meeting can be found on the
conference website:
http://accscientificsession.acc.org/ACC.aspx.
Data from this study were previously presented at the American
College of Cardiology 62nd Annual Scientific Session and Expo.
About Cimaglermin alfa
Cimaglermin alfa is a recombinant version of a naturally
occurring growth factor that is important for cardiac development
and function. In clinical development for heart failure, it may
offer a unique mechanism. In preclinical studies, cimaglermin alfa
acted at the level of the muscle cells, or cardiomyocytes, and is
hypothesized to restore cardiomyocyte functions that are impaired
in heart failure, potentially improving the heart's ability to
contract and pump blood. In preclinical studies and in a Phase 1
trial, cimaglermin alfa resulted in improved contractile function.
Preclinical studies suggest that it may also protect the heart
structure from acute and chronic stressors.
Cimaglermin alfa is also being investigated in preclinical
studies as a treatment for neurological conditions such as stroke
and peripheral nerve damage.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a
biotechnology company focused on developing therapies that restore
function and improve the lives of people with neurological
disorders.
Acorda markets three FDA-approved therapies, including
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a
treatment to improve walking in patients with multiple sclerosis
(MS), as demonstrated by an increase in walking speed. The Company
has one of the leading pipelines in the industry of novel
neurological therapies. Acorda is currently developing a number of
clinical and preclinical stage therapies. This pipeline addresses a
range of disorders including post-stroke walking deficits,
Parkinson’s disease, epilepsy, heart failure, MS and spinal cord
injury.
For more information, please visit the Company’s website
at: www.acorda.com.
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical facts,
regarding management's expectations, beliefs, goals, plans or
prospects should be considered forward-looking. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially, including the ability to realize the
benefits anticipated from the Civitas transaction and to
successfully integrate Civitas' operations into our operations; our
ability to successfully market and sell Ampyra in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz, or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully
market CVT-301, Plumiaz, or any other products under development;
we may need to raise additional funds to finance our expanded
operations and may not be able to do so on acceptable terms; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence
on our collaboration partner Biogen Idec in connection therewith;
competition; failure to protect our intellectual property, to
defend against the intellectual property claims of others or to
obtain third party intellectual property licenses needed for the
commercialization of our products; and, failure to comply with
regulatory requirements could result in adverse action by
regulatory agencies.
These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission.
Acorda may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this release are made only as of the date hereof, and Acorda
disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this release.
Acorda TherapeuticsJeff Macdonald,
914-326-5232jmacdonald@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2023 to Mar 2024